Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · March 12, 2024

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
J. Clin. Oncol 2024 Feb 21;[EPub Ahead of Print], YY Janjigian, JA Ajani, M Moehler, L Shen, M Garrido, C Gallardo, L Wyrwicz, K Yamaguchi, JM Cleary, E Elimova, M Karamouzis, R Bruges, T Skoczylas, A Bragagnoli, T Liu, M Tehfe, T Zander, R Kowalyszyn, R Pazo-Cid, M Schenker, K Feeny, R Wang, M Lei, C Chen, R Nathani, K Shitara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading